Medical robotics company Neural Analytics, Inc. has secured USD22 million in Series C funding round to support its Lucid robot-assisted brain ultrasound device. This round which brings the company’s total funding to nearly USD66 million was led by Alpha Edison and the Company has also issued warrants to purchase stock in connection to the financing.
Based in Los Angeles, CA, Neural Analytics’ Lucid robotic system is a robotically assisted ultrasound system for brain health assessment. It integrates the Lucid M1 transcranial doppler system with the NeuralBot platform, designed to non-invasively search, measure and display objective brain blood flow information under the guidance of a care provider. The company’s technology combines ultrasound, robotics, and Machine Learning to enable neurologists with critical information regarding brain health to make clinical decisions and advance patient outcomes. Currently, the Lucid Robotic System is active at select healthcare locations across the United States and Neural Analytics will reportedly continue to expand its commercialization.
Recently, Neural Analytics introduced the CODEX study, a prospective, single-arm, global multi-center study of an investigational iteration of the Lucid system, which intends to explore the technical feasibility of the platform in a wider range of patients and neurological pathologies. Neural Analytics Co-Founder and CEO Leo Petrossian said that “Over the past six years we have worked very hard to develop and validate new technologies into impactful products. Though the culmination of years of our work into U.S. FDA clearance & European CE mark was a meaningful milestone in 2018, it was only the start of our journey. With this financing, Neural Analytics will be able to launch the Lucid Robotic System into clinical environments where it will have the greatest impact on patient outcomes.”